Answers are grounded in this paper and cite their sources.
Our report confirms the prognostic value of HIF-1 alpha when restricted to poorly differentiated serous ovarian carcinoma. In addition it shows that this association is elusive, since it is not only methodology-related but it can be antibody-depended. There is adequate evidence to speculate that targeting HIF-1 alpha could improve the long-term prognosis of these patients In order to increase the overall sensitivity of the immunoassay, maintaining acceptable levels of specificity, a panel of antibodies should be used.
No takes yet. Share an insight, caveat, or question.
Daponte et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: